I was trained to see menopause hormone therapy mainly as a list of dangers: breast cancer, blood clots, stroke, and the possibility of doing more harm than good.
I still take those risks seriously. But I no longer see them as the whole story.
The evidence I learned was important, yet it did not answer every question about who might benefit, when treatment might be safest, or how different hormone therapies compare. What once felt like a straightforward reason to avoid prescribing now feels like a decision that requires context, individualized risk assessment, and a willingness to revisit old assumptions.
One thing about practicing medicine: the learning doesn’t end when you graduate.
Neither do the exams, unfortunately. But that’s a different blog post.
Medical school and residency give us a foundation. Being a physician means continuing to build on it—and sometimes revisiting an opinion we thought was settled.
For me, one of those subjects is hormone therapy for menopause, often called hormone replacement therapy, or HRT.
The Message I Took Away From Training
In my experience, menopause hormone therapy received limited attention during training. The message I carried away emphasized caution and reasons to avoid prescribing it. I left feeling more familiar with the concerns than confident about when treatment might be appropriate.
That shaped my perspective.
When you’re responsible for someone’s health, you take potential harm seriously. But I’m learning that good care also requires asking whether my understanding of those risks is complete—and whether it reflects the evidence available today.
A More Nuanced Conversation
Much of the concern surrounding hormone therapy grew out of the Women’s Health Initiative, or WHI, a large set of randomized clinical trials that began in the 1990s. The trials were not designed to answer every question about menopause treatment. They studied specific hormone regimens in a broad group of postmenopausal women, many of whom were older and farther from menopause than the patients who typically seek treatment for new symptoms.
The WHI results raised important concerns, including increased risks of stroke and blood clots with some systemic estrogen-progestogen regimens. The estrogen-plus-progestogen trial also found an increased risk of breast cancer after several years of use, while the estrogen-alone trial in women who had undergone hysterectomy did not show the same breast-cancer pattern during the trial period. These findings were important, but they applied to the treatments studied and could not automatically be generalized to every hormone product, dose, route, or patient.
Later analyses and other research have emphasized that age and timing matter. The average participant in the WHI hormone trials was about 63, and many participants were more than 10 years beyond menopause. That is different from a healthy person in her 40s or 50s who is considering treatment for bothersome symptoms soon after menopause begins. It does not mean that starting hormone therapy early is risk-free, or that treatment is appropriate for everyone. It means that the balance of potential benefits and risks may differ depending on when treatment starts, a person’s health history, and the treatment being considered. (fda.gov)
This understanding has developed over years. It isn’t simply a new announcement that hormones are “good” after previously being “bad.”
Current guidance generally supports individualized decision-making rather than routine treatment for everyone or a blanket prohibition. For healthy women younger than 60 or within 10 years of menopause onset who have bothersome vasomotor symptoms, such as hot flashes and night sweats, and no contraindications, systemic hormone therapy may have a favorable benefit-risk balance. The decision still requires a discussion of personal risk factors, treatment goals, alternatives, and the lowest effective dose for the appropriate duration. Starting systemic therapy after age 60 or more than 10 years after menopause generally has a less favorable balance because the absolute risks of cardiovascular disease, stroke, blood clots, and dementia are more likely to be higher. (pubmed.ncbi.nlm.nih.gov)
Treatment type matters, too. Systemic therapy—such as oral or transdermal estrogen—circulates throughout the body and is used primarily for symptoms such as hot flashes and night sweats. If a person has a uterus, systemic estrogen generally needs to be paired with adequate progestogen to protect the uterine lining; estrogen alone is not appropriate in that situation. The route and formulation may affect risk. For example, transdermal estrogen may have a different clotting profile from oral estrogen, but it is not risk-free.
Low-dose vaginal estrogen is different. It is used primarily for genitourinary symptoms, such as vaginal dryness, pain with sex, and some urinary symptoms. Compared with systemic therapy, it results in much lower circulating estrogen levels and is generally considered separately when assessing risks and contraindications. Even so, it is not automatically appropriate for everyone, and people with a history of estrogen-sensitive cancer or other complex medical conditions may need individualized guidance, coordination with specialists, or consideration of nonhormonal options.
“Menopause hormone therapy” is therefore not a single treatment with a single risk profile. The route, dose, formulation, indication, presence or absence of a uterus, age, time since menopause, medical history, and personal preferences all matter. (menopause.org)
That is a much more useful conversation than a blanket yes or no.
What Has Helped Me Reconsider
Learning through Dr. Rachel Rubin’s educational work has encouraged me to revisit this topic and look more closely at the evidence.
It has also prompted me to think about how we discuss symptoms that women may feel uncomfortable bringing up—or may have been told are simply part of getting older.
Menopause is a normal life stage. That doesn’t make its effect on someone’s quality of life unimportant.
At the same time, hormone therapy isn’t appropriate for everyone. Symptoms, age, time since menopause, medical history, family history, personal preferences, and the specific treatment all matter. A history of certain cancers, unexplained vaginal bleeding, blood clots, stroke, heart attack, liver disease, or other conditions may make systemic therapy inappropriate or require specialist input. These considerations do not apply identically to low-dose vaginal estrogen, but they still warrant careful review in the context of the individual patient.
Nonhormonal options deserve a place in the discussion, too. (menopause.org)
My perspective has moved toward asking better questions about who might benefit, what the risks are for that person, and how to help her make an informed decision.
Where I Am Right Now
I want to be honest: I’m not quite comfortable prescribing menopausal hormone therapy independently yet.
I’m getting closer.
I’m continuing to learn about patient selection, treatment options, contraindications, and follow-up. I want my confidence to rest on a sound understanding of how to prescribe thoughtfully and monitor appropriately.
Enthusiasm is useful. It is not, by itself, a prescribing qualification.
Until I’m ready, I can listen, take symptoms seriously, discuss options within my expertise, and help patients connect with a clinician experienced in menopause care.
Being Willing to Reconsider
I don’t want to hold onto an opinion simply because it was the one I learned first. I also don’t want to adopt a treatment simply because it has become a popular topic.
The lesson, for me, is not that I was wrong to be cautious. It’s that caution without continued learning can become a barrier to patient-centered care. Patients deserve more than the limits of what I happened to learn in training. They deserve a clinician willing to revisit old assumptions, weigh current evidence, listen to what matters to them, and be honest about what they do and don’t know.
That means staying curious, recognizing the limits of my expertise, and continuing my education—not because I need to have every answer immediately, but because my patients deserve care that keeps evolving.
I may be the physician in the room, but I’m a lifelong learner, too. And sometimes the most responsible thing I can do is admit that, keep learning, and make sure the patient is connected with someone who can help until I have the information and experience I need to develop a treatment plan myself.